Abstract
In a recent meta-analysis we evaluated the effectiveness of prophylactic intra-aortic balloon pump (IABP) support in patients at high-risk PCI (HR-PCI) on 7 randomized controlled trials (RCTs) and 4 Observational studies (Obs.) [1]. The primary endpoint was the in-hospital mortality and the composite of major adverse cardiac and cardiovascular events (MACCE) was considered the secondary endpoint. Data on MACCE were available only in 5 RCTs and in 3 Obs. The best level of evidence coming from RCTs was in agreement with the results obtained from Obs., as showed by the test for subgroup differences which always showed a value of I2 equal to zero, for both RR and RD, on the primary and the secondary endpoints [1].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
